Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.40 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.40 |
| ▸ | OPRD1 known ✓ | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30427479 | 1.00 | BRD4 (0.40) | BRD4OPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL567321 | 0.98 | BRD4 (0.41) | BRD4OPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5215702 | 0.98 | BRD4 (0.41) | BRD4OPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL567320 | 0.98 | BRD4 (0.41) | BRD4OPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15760245 | 0.88 | OPRM1 (0.46) | BRD4OPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL630094 | 0.85 | OPRM1 (0.48) | BRD4OPRM1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL25271505 | 0.82 | BRD4 (0.46) | BRD4OPRM1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL23363609 | 0.81 | NPSR1 (0.36) | MEN1KMT2A | |
| SCHEMBL1963692 | 0.80 | BRD4 (0.47) | BRD4OPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2811875 | 0.79 | OPRM1 (0.42) | BRD4OPRM1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| CN-114846013-B | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2024-12-20 | — | — | CN | disclosed |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| EP-4071147-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | Lg Chem, Ltd. (KR) | 2022-10-12 | — | — | EP | disclosed |
| CN-114846013-A | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2022-08-02 | — | — | CN | disclosed |
| WO-2021133035-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2021-07-01 | — | — | WO | disclosed |
| US-10960007-B2 | Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2021-03-30 | — | — | US | disclosed |
| US-20200061068-A1 | Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | RICHTER GEDEON NYRT. (HU) | 2020-02-27 | — | — | US | disclosed |
| EP-3596079-A1 | PHARMACOLOGICALLY ACTIVE ARYL-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2020-01-22 | — | — | EP | disclosed |
| WO-2018167629-A1 | PHARMACOLOGICALLY ACTIVE ARYL-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2018-09-20 | — | — | WO | disclosed |
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| EP-1165540-B1 | TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2003-08-13 | — | — | EP | disclosed |
| US-6458830-B1 | THE COMPOUNDS ARE OF PARTICULAR USE IN THE TREATMENT OR PREVENTION OF DEPRESSION, ANXIETY, PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTHERPETIC NEURALGIA. | MERCK SHARP & DOHME LTD. | 2002-10-01 | — | — | US | disclosed |
| EP-1165540-A1 | TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056727-A1 | TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | OPRM1 572/4885SLC6A2 3514/4885SLC6A4 3102/4885 |
| US-20200061068-A1 | Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | GABRA5, P2RX5, P2RY1 | OPRM1 153/4885SLC6A2 494/4885SLC6A4 220/4885 |
| US-10960007-B2 | Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, P2RX5, P2RY1 | OPRM1 153/4885SLC6A2 494/4885SLC6A4 220/4885 |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | DGAT2, DGAT1, PLAAT2 | OPRM1 4321/4885SLC6A2 674/4885SLC6A4 1189/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | OPRM1 1673/4885SLC6A2 539/4885SLC6A4 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.